Nordic | Biotech & Healthcare Your insights to listed Danish & Nordic biotech & healthcare stocks. We keep you updated on their news flow including updates on clinical trials, acquisitions, insider trading, price targets, right issues, etc. We also present the top 3 best-performing stocks in the Nordics each week.

The past week was full of news; Fluoguide met the primray endpoint in a fase 2 trial against brain cancer, Ascendis Pharma resubmitted a NDA for TransCon to FDA, and Evaxion Biotech had further developments of its AI-model predicting reposnses to cancer immunothereapy. Furthermore, several companies reported Q3-earnings.

In the past week, 14 of the 20 listed Danish biotech companies published news. 10 of the 20 companies had a positive share price development the past week and 9 companies have had a positive share price performance year-to-date. Cessatech continues to be the best performing stock year-to-date with a 161% increase.

---

Do you want to stay tuned to the developments of impact companies and stocks in the Nordics? Then we have something for you! We have launched a brand new newsletter that dives into impact stocks listed in the Nordics. The newsletter help you to invest more sustainably in the businesses of tomorrow, track the development of multiple sectors including energy production, waste management, and carbon capture, and follow the developments of over 100 large, medium and small cap companies. Read the first edition here.

---

Danish Company news the past week

Ascendis Pharma

Ascendis Pharma Resubmits NDA for TransCon™ PTH to the U.S. FDA (Link)

Biosergen

No news the past week

Cessatech

Third Quarter Report Q3-2023 (Link)

CS Medica

CS Medica postponed the Q4 2022/2023 quarterly report until Wednesday 22. November 2023

Curasight

No news the past week

Evaxion Biotech

Evaxion Presents Proof-of-Principle for Its Unique AI Model Predicting Responses to Cancer Immunotherapy (Link)

ExpreS2ion

ExpreS2ion announces financial results for the third quarter 2023 (Link)

Fluoguide

FluoGuide announces FG001 meets primary endpoint in phase llb trial in aggressive brain cancer (Link)

Genmab

No news the past week

Gubra

No news the past week

Initiator Pharma

No news the past week

IO Biotech

IO Biotech Appoints Helen Collins, MD, to its Board of Directors (Link)

IO Biotech Announces 2023 Third Quarter Results (Link)

Pila Pharma

Pila Pharma published new about an upcomming rights issue (Link)

Saniona

Saniona’s upcoming presentations on November 22 and 23 (Link)

Scandion Oncology

Scandion Oncology presents its Q3-earnings on November 2022 (Link)

SynAct Pharma

SynAct Pharma comments on ownership changes in Bioinvest Aps (Link)

ViroGates

No news the past week

Zealand Pharma

Zealand Pharma Increases its Share Capital as a Consequence of Exercise of Employee Warrants (Link)

Y-mAbs Therapeutics

Y-mAbs Reports Third Quarter 2023 Financial Results and Recent Corporate Developments (Link)

2cureX

Bulletin from the extraordinary general meeting in 2CureX AB (Link)

SELECTED CASES

SHARE PRICE DEVELOPMENTS – Dansih stocks

On average, the Danish biotech and healthcare stocks delivered a positive share price performance last week of 1.3%. Saniona AB became the best-performer, while the stock has also done phenomenally year-to-date now. Pila Pharma also did well with a 12% increase following news about its rights issue, while IO Biotech rose 10% following their Q3-earnings. IO Biotech currently has a market cap. of 66 MUSD, while sitting on a cash pile of 166 MUSD and liabilities of 15 MUSD. The best stocks year-to-date include Curasight, Cessatech, Fluoguide, and Saniona after soaring 88-161%. Overall, the Danish biotech and healthcare stocks are in negative territory this year with a year-to-date return of -3.3%.

Read more about Curasight (in Danish): Positive studiedata mod lungekræft styrker Curasights stærke kursudvikling

Overview of share price developments the past week, year-to-date and last twelve months

In the past week, the Kapital Partner Nordic Healthcare Index (KPHC) rose 1.8% to 61.04. Kapital Partner Nordic Healthcare Index tracks all biotech & healthcare companies in the Nordics. It includes large-cap companies such as Novo Nordisk and Genmab as well as smaller companies such as Curasight. In the past 12 months, it has significantly underperformed relative to the C25-index in Copenhagen and S30-index in Stockholm, while the Kapital Partner Nordic Growth Exchanges index (KPNGX) has followed the KPHC-index’s downward trajectory.

The index development for Kapital Partner Healthcare Index the past 12 months

34-58% in weekly retrun for the three best performing Nordic biotech & healthcare stocks the past week

Lumito AB (58%) (Nordnet) specializes in medical technology for digital pathology. The company strives to improve tissue diagnostics with its patented technology based on upconverted nanoparticles. The company plans to initially launch its first product for research laboratories.

Dicot AB (49%) (Nordnet) is developing the drug candidate LIB-01, which is expected to be a potency drug to treat erectile dysfunction and premature ejaculation. Duration of action and fewer side effects are main desired properties. Dicot’s main strategy is to develop LIB-01 in-house up to and including clinical phase 2a study, and then in partnership with major pharmaceutical companies to finance and further develop LIB-01 into a registered drug for the world market. In the past week, the company got 16.5 MSEK before costs via warrants of series TO5 (Link)

Pharmacolog I Uppsala AB (34%) (Nordnet)  offers security solutions adapted for actors in healthcare. The services are used for the administration of intravenous medicine to prevent common administration errors, which is important in the treatment of cancer and severe diseases. Important factors to consider when treating include sterility, concentration, and recommendations. The stock rose following release of its Q3-earnings (Link)

Sources: Refinitiv & Nordnet